{"log_id": 1335293191808733865, "direction": 0, "words_result_num": 25, "words_result": [{"probability": {"variance": 3e-05, "average": 0.996825, "min": 0.97764}, "location": {"width": 436, "top": 185, "height": 46, "left": 202}, "words": "西格列汀与二甲双胍和格列美脲联合治疗"}, {"probability": {"variance": 0.004746, "average": 0.983047, "min": 0.581395}, "location": {"width": 831, "top": 224, "height": 56, "left": 202}, "words": "在一项为期24周的安慰剂对照试验中,接受格列美脲≥4mg/天和二甲双胍≥"}, {"probability": {"variance": 0.006829, "average": 0.979463, "min": 0.521511}, "location": {"width": 833, "top": 272, "height": 56, "left": 204}, "words": "500mg/天治疗但血糖控制不佳的2型糖尿病患者随机添加西格列汀100mg/天和"}, {"probability": {"variance": 0.002815, "average": 0.983326, "min": 0.736224}, "location": {"width": 833, "top": 321, "height": 53, "left": 206}, "words": "安慰剂治疗(磷酸西格列汀,N=116;安慰剂,N=113)。在接受磷酸西格列"}, {"probability": {"variance": 0.004251, "average": 0.987205, "min": 0.601718}, "location": {"width": 830, "top": 367, "height": 54, "left": 207}, "words": "汀治疗的患者中发生率≥5%(并且比接受安慰剂患者更常见)的不良反应(无论"}, {"probability": {"variance": 3.3e-05, "average": 0.996236, "min": 0.98063}, "location": {"width": 763, "top": 418, "height": 49, "left": 209}, "words": "研究者对因果关系的评估如何)是:低血糖(表3)和头痛(6.9%,2.7%)"}, {"probability": {"variance": 5.8e-05, "average": 0.995489, "min": 0.970188}, "location": {"width": 434, "top": 515, "height": 43, "left": 212}, "words": "西格列汀与二甲双胍和罗格列酮联合治疗"}, {"probability": {"variance": 0.000105, "average": 0.994979, "min": 0.959873}, "location": {"width": 831, "top": 551, "height": 54, "left": 213}, "words": "在一项安慰剂对照的研究中,磷酸西格列汀100mg做为添加治疗用于接受二甲"}, {"probability": {"variance": 0.000118, "average": 0.995292, "min": 0.948779}, "location": {"width": 826, "top": 600, "height": 52, "left": 216}, "words": "双胍和罗格列酮治疗但血糖控制不佳的2型糖尿病患者(磷酸西格列汀,N=181"}, {"probability": {"variance": 0.001538, "average": 0.984834, "min": 0.779172}, "location": {"width": 825, "top": 647, "height": 53, "left": 218}, "words": "安慰剂,N=97)。第18周,西格列汀治疗组的患者(N=170)中报告发生率≥"}, {"probability": {"variance": 4.5e-05, "average": 0.997669, "min": 0.961301}, "location": {"width": 833, "top": 696, "height": 50, "left": 215}, "words": "5%且比接受安慰剂患者(N=92)更常见的不良反应(无论研究者对因果关系的"}, {"probability": {"variance": 0.000386, "average": 0.992416, "min": 0.913824}, "location": {"width": 831, "top": 743, "height": 50, "left": 218}, "words": "评估如何)是:上呼吸道感染(磷酸西格列汀,5.5%;安慰剂,5.2%)和鼻咽"}, {"probability": {"variance": 0.012399, "average": 0.963222, "min": 0.457924}, "location": {"width": 831, "top": 789, "height": 53, "left": 220}, "words": "炎(6.1%,4.1%)。第54周,西格列汀治疗组的患者中报告发生率二5%比接受"}, {"probability": {"variance": 0.003012, "average": 0.98696, "min": 0.670877}, "location": {"width": 826, "top": 836, "height": 52, "left": 223}, "words": "安慰剂患者更常见的不良反应(无论研究者对因果关系的评估如何)是:上时吸"}, {"probability": {"variance": 0.00086, "average": 0.982162, "min": 0.873296}, "location": {"width": 830, "top": 884, "height": 53, "left": 222}, "words": "道感染(磷酸西格列汀,15.5%;安慰剂,6.2%)、鼻咽炎(11.0%,9.3%)、周"}, {"probability": {"variance": 0.000204, "average": 0.989718, "min": 0.946575}, "location": {"width": 530, "top": 941, "height": 41, "left": 224}, "words": "围性水肿(8.3%,5.2%)以及头痛(5.5%,4.1%)"}, {"probability": {"variance": 5.8e-05, "average": 0.996333, "min": 0.96745}, "location": {"width": 409, "top": 1030, "height": 41, "left": 227}, "words": "西格列汀与二甲双胍和胰岛素联合治疗"}, {"probability": {"variance": 0.000224, "average": 0.995076, "min": 0.911542}, "location": {"width": 830, "top": 1069, "height": 50, "left": 228}, "words": "在一项24周安慰剂对照的研究中,磷酸西格列汀100mg做为添加治疗用于接受"}, {"probability": {"variance": 0.002324, "average": 0.987189, "min": 0.716596}, "location": {"width": 826, "top": 1117, "height": 49, "left": 231}, "words": "二甲双胍(≥1500mg/日)和胰岛素治疗但血糖控制不佳的2型糖尿病患者。在"}, {"probability": {"variance": 0.003548, "average": 0.983591, "min": 0.64996}, "location": {"width": 827, "top": 1164, "height": 48, "left": 231}, "words": "接受磷酸西格列汀治疗的患者中发生率二5%且比接受安慰剂患者(N=233)更常"}, {"probability": {"variance": 4e-06, "average": 0.999004, "min": 0.989509}, "location": {"width": 776, "top": 1213, "height": 45, "left": 233}, "words": "见的不良反应(无论研究者对因果关系的评估如何)是低血糖(参见表3)"}, {"probability": {"variance": 4.4e-05, "average": 0.994272, "min": 0.984847}, "location": {"width": 75, "top": 1318, "height": 27, "left": 235}, "words": "低血糖"}, {"probability": {"variance": 1e-05, "average": 0.99779, "min": 0.985863}, "location": {"width": 828, "top": 1346, "height": 47, "left": 235}, "words": "当磷酸西格列汀和二甲双胍联用与磺酰脲类或胰岛素同时给药时,报告至少一次"}, {"probability": {"variance": 6e-06, "average": 0.998421, "min": 0.98943}, "location": {"width": 829, "top": 1393, "height": 48, "left": 235}, "words": "低血糖不良反应(无论研究者对因果关系的评估如何)的患者百分比高于安慰剂"}, {"probability": {"variance": 2.7e-05, "average": 0.99623, "min": 0.979031}, "location": {"width": 719, "top": 1443, "height": 44, "left": 238}, "words": "和二甲双胍与磺酰脲类或胰岛素同时给药观察到的百分比(参见表3)"}], "language": 3}